

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



杭州啓明醫療器械股份有限公司
Venus Medtech (Hangzhou) Inc.

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2500)

APPOINTMENT OF JOINT CHIEF EXECUTIVE OFFICER

The board (the “**Board**”) of directors (collectively, the “**Directors**” and each, a “**Director**”) of Venus Medtech (Hangzhou) Inc. (the “**Company**”) hereby announces that Mr. Lim Hou-Sen (Lin Haosheng) (“**Mr. Lim**”) has been appointed as the joint chief executive officer of the Company with effect from September 22, 2023.

Biographical details of Mr. Lim are set out as follows:

Mr. Lim Hou-Sen (Lin Haosheng) (林浩昇), aged 49, is the senior vice president of oversea affairs of the Company. Mr. Lim joined the Group in December 2016 as the chief technology officer. Mr. Lim is primarily responsible for business operations, regulatory approvals, quality control and commercial suitability and sustainability of products of the Group. Mr. Lim served as an executive Director of the Company from November 2018 to January 2023.

Mr. Lim has more than 20 years of industry experience. Prior to joining our Group, Mr. Lim was the managing director and chief technology officer of Transcatheter Technologies GmbH, a medical device company incorporated in Germany, which primarily focuses on heart valve implantation and aortic therapy solutions, from January 2009 to October 2016. From September 2005 to December 2008, Mr. Lim was the founder and served as the chief executive officer of EndoCor Pte. Ltd., a company incorporated in Singapore, which develops minimally invasive heart valve and medical devices in the structural heart space. From March 2003 to December 2008, Mr. Lim was a managing director in a biomedical company named Embryon, Inc., which primarily engages in research and experimental development on biotechnology, life and medical science.

Mr. Lim received a bachelor’s degree in mechanical engineering from Nanyang Technological University in Singapore in July 1999 and a master’s degree of engineering from Nanyang Technological University in Singapore in June 2002.

Save as disclosed in the announcement and as of the date of this announcement, Mr. Lim confirms that (i) he currently does not, nor did he in the past three years, hold any directorships or supervisorship in any listed companies or any other major positions in the Company and its subsidiaries; (ii) he does not have any relationship with any Directors, supervisors, senior management or substantial or controlling shareholders of the Company; and (iii) he does not have any interest in the securities of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)). In addition, Mr. Lim has confirmed that there is no other matter relating to his appointment that needs to be brought to the attention of the Shareholders, and there is no other information that needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

Mr. Lim will enter into a service contract with the Company in respect of his appointment as the joint chief executive officer of the Company for an initial term of three years commencing from the date of this announcement. Mr. Lim will be entitled to a fixed remuneration of RMB935,268 per year and bonus payable at the discretion of the Board, determined with reference to the prevailing market conditions and Mr. Lim's effort and expertise. Mr. Lim's remuneration and other benefits are subject to review by the Board from time to time.

By Order of the Board
Venus Medtech (Hangzhou) Inc.
Min Frank Zeng
Chairman

Hangzhou, September 22, 2023

As at the date of this announcement, the executive Directors are Mr. Min Frank Zeng, Mr. Zhenjun Zi and Ms. Meirong Liu; the non-executive Director is Mr. Ao Zhang; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu, Mr. Wan Yee Joseph Lau and Mr. Chi Wai Suen.